“500 lives saved during the relatively young life of this technology is a remarkable accomplishment and great example of how innovation in military medicine benefits the broader public.” says Dr. Todd E. Rasmussen
SAN ANTONIO (PRWEB) December 05, 2019
PRYTIME MEDICAL™ today announced the 500th documented life saved using the ER-REBOA™ Catheter. This milestone is in line with the company’s mission: No one should bleed to death and the sooner you stop bleeding, the better.
Teams of civilian and military physicians, nurses and technicians around the world are now adopting Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) as a less invasive approach to control bleeding and shock.
“The ER-REBOA™ Catheter has now played a role in 500 documented lives saved,” said David Spencer, CEO of Prytime. “Our team is excited about this milestone, because we pride ourselves on supporting comprehensive ER-REBOA™ programs, not just selling a catheter.”
This comprehensive approach has led to ER-REBOA™ adoption at over 400 U.S. hospitals, including 170 Level I trauma centers, and in 16 countries worldwide. “Physicians continue to innovate in this space, using REBOA much earlier in the hemorrhage control and resuscitation process,” Spencer said. “We are positioning our company to support this evolving trend.”
“500 lives saved during the relatively young life of this technology is a remarkable accomplishment and great example of how innovation in military medicine benefits the broader public,” says Air Force Col. (Dr.) Todd E. Rasmussen.
Dr. Rasmussen, who is also one of the original inventors of the technology, adds “The fact that the catheter is now being studied and used by the U.S. and allied militaries is also a substantial success for the U.S. military’s medical research and development program. It’s gratifying to see an idea that came from our experience in, and study of, casualty care come to realization and play such a significant role in saving lives around the world.”
Prytime Medical is committed to innovating and developing next-generation REBOA technology that meets the needs of the clinical community and its patients. Prytime is relentlessly pursuing new ways to improve ease of use of the device, and to mitigate undesired effects of REBOA. Prytime anticipates introducing these new products to the U.S. market in 2020.
To learn more about Prytime Medical™ and the ER-REBOA™ Catheter, click here: http://www.prytimemedical.com
About Prytime Medical Devices, Inc.
Prytime Medical Devices, Inc. designs, develops and commercializes minimally invasive solutions for hemorrhage control. We are proud to be a part of bringing military medical innovation to the civilian marketplace. We believe no one should bleed to death, and the sooner you stop bleeding the better.
The underlying intellectual property for the ER-REBOA™ Catheter was conceived by experienced military vascular surgeons Dr. Todd Rasmussen and Dr. Jonathan Eliason, based on lessons learned in combat and an unrelenting desire to improve survival from wartime injury. Dr. Rasmussen who commented for this press release has no financial relationship with and receives no payments from Prytime Medical. Dr. Rasmussen receives no royalties from the sale of the ER-REBOA™ Catheter.